Salarius Pharmaceuticals, Inc. (SLRX) Completes SP-3164 Related Meeting with FDA, Plans to Submit IND in 2023
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/14/2024
- Nasdaq hits record close after Powell reassures investors, CPI in focus
- Powell says Fed's restrictive policy is working
- JPMorgan says not worth 'taking on equity risk' now
- Alphabet debuts beefed-up AI search and chatbot as competition heats up
- World stock index set for record high, dollar dips after PPI, Powell
- GameStop (GME) Halted on Circuit Breaker, Up 54%
- AMC Entertainment (AMC) Halted on Circuit Breaker, Up 121%
- Andy Jassy makes AWS leadership announcement (AMZN), says Matt Garman will become CEO of AWS
- Squarespace, Inc. (SQSP) To Go Private For $44/shr In Cash With Permira
- GameStop (GME) Halted Again on Volatility, Up 69%
- After-hours movers: AMC Entertainment, DLocal, Boot Barn, and more
- Midday movers: GameStop, AMC Entertainment rise; Alibaba falls
- After-hours movers: AMC Entertainment, StoneCo, Fulcrum Therapeutics, and more
- Midday movers: Intel, Arm, Apple, GameStop rise; Alphabet falls
- Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
May 11, 2022 4:05 PM EDTHOUSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, hematologic cancers and other cancers, today announced the successful completion of its pre-IND (Investigational New Drug) meeting process with the U.S. Food and Drug Administration (FDA) for SP-3164. SP-3164 is a next-generation targeted protein degrader that induces... More
